CLDN1 and cholangiocarcinoma: Here, we demonstrate evidence to support the use of a panel of fluorescently labeled peptides specific for EGFR, claudin-1, and ErbB2 to distinguish BilIN, the precursor lesion, and cholangiocarcinoma from normal biliary epithelium.